Zambon Company S.p.A.
https://www.zambonpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zambon Company S.p.A.
Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic
The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Roche Adds Ascidian’s RNA-Writing To Its Neurology Push
A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as the Swiss firm expands its gene editing and neuroscience efforts.
Newron Enters New Year With High Hopes For Evenamide
All being well, the Italian firm will soon have the results from a late-stage study of evenamide in schizophrenia patients who show an inadequate response to atypical antipsychotics.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Company Information
- Industry
- Diversified
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Breath Therapeutics Holding BV
- Breath Therapeutics GmbH (BREATH)
- Profile Pharma
- Zambon S.p.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice